Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Organovo undisclosed small molecule (Crohn's Disease)
- Development stage
- Preclinical
- Lead developer
- Organovo
- Modality
- Small Molecules
01
Overview
This undisclosed small molecule drug candidate is being developed by Organovo for the treatment of Crohn's disease and inflammatory bowel disease (IBD). The drug's biological target was identified and validated using Organovo's proprietary 3D human tissue models, which aim to recapitulate the complex architecture and microenvironment of the diseased intestine. As of 2023, the program is in the preclinical stage, with medicinal chemistry efforts underway to optimize the lead compound. Organovo expects to file an Investigational New Drug (IND) application for this candidate by the end of 2025. This program is distinct from the company's other IBD candidate, FXR314, which is an FXR agonist.
- Other names
- Novel Drug to Undisclosed Target
Beyond the preview
Go deeper on Organovo undisclosed small molecule (Crohn's Disease).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Organovo undisclosed small molecule (Crohn's Disease).